Cytokind: the overall objective of this contract is to provide clinical validation for the treatment of covid with NB-UVB therapy. A submission to the FDA for a new indication will be made.
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50122C00064
- Awardee
-
Cytokind Inc. UEI ESXSVJEX6E33
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $144,415
Award facts
- Opportunity
-
- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement Solicitation · BAA20100SOL0002 · Posted Feb 3, 2020
- Contract value 100% obligated
- $144,415.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 100 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Exeter, NH 03833, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$604,585 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $749,000 |
About this award
Cytokind Inc. was awarded a firm fixed price definitive contract valued at $749,000 by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The objective of this contract is to provide clinical validation for the treatment of COVID-19 with narrowband ultraviolet B therapy through a trial comparing NB-UVB to placebo in high-risk hospitalized patients. Data generated under this contract will support a submission to the FDA for a new indication. The work will be performed in Exeter, New Hampshire over a 21-month period concluding in June 2024. This award was made under Special Instructions 019 to the HHS Easy Broad Agency Announcement BAA-20-100-SOL-0002 seeking host-directed therapeutic candidates to aid long-term outcomes from lung injury.
Quick answers
Who was awarded contract 75A50122C00064?
75A50122C00064 was awarded to Cytokind Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 19, 2022.
How much is contract 75A50122C00064 worth?
The government has obligated $144,415 on 75A50122C00064.
Was contract 75A50122C00064 competed?
The extent of competition for 75A50122C00064 was competed under sap. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award